Keyword: Praluent

Amgen escalates PCSK9 war with permanent Repatha price cut

Friday, October 25, 2019

Amgen has permanently cut the list price of its PCSK9 cholesterol drug Repatha from $14,520 to $5,850, but it may not be enough to boost demand.

Medicines Co.'s PCSK9 challenger has reassuring data

by Angus Liu

Monday, September 2, 2019

Phase 3 data for PCSK9-targeting RNAi drug inclisiran show it has the efficacy and clean safety profile to hang with Repatha and Praluent.

Praluent, Repatha face major new PCSK9 threat

by Angus Liu

Tuesday, August 27, 2019

The Medicines Company's inclisiran, boasting a similar efficacy and safety profile but better convenience, could become the PCSK9 of choice, one analyst says.

Dupixent powers Regeneron's Sanofi collab to first-ever profit

by Eric Sagonowsky

Tuesday, August 6, 2019

More than a decade in, Sanofi and Regeneron's antibody partnership has spawned several drugs, but it took Dupixent to fuel its first profit.

With patent win, Amgen ready to block PCSK9 rivals in Germany

by Eric Sagonowsky

Friday, July 12, 2019

As a high-profile PCSK9 patent battle plays out in the U.S., Amgen won an injunction in Germany blocking Praluent, Sanofi and Regeneron's rival med.

Smartphones are the latest target for pharma's waiting room ads

by Beth Snyder Bulik

Wednesday, July 3, 2019

Data-as-a-service provider Semcasting uses IP address targeting to serve pharma ads to patients’ smartphones in the waiting room.

Dupixent's rolling in asthma, but COPD's tougher: Regeneron CEO

by Angus Liu

Tuesday, May 7, 2019

Dupixent has shown efficacy in multiple inflammations, but Regeneron CEO Len Schleifer wouldn't list COPD an indication it has "high confidence in."

Sanofi, Regeneron score a Praluent boost with new CV nod

by Eric Sagonowsky

Monday, April 29, 2019

Sanofi and Regeneron haven't seen the uptake they'd hoped for with Praluent, but now they've won a label expansion detailing the drug's CV benefits.

Amgen rolls toned-down TV ad for cholesterol-fighting Repatha

by Beth Snyder Bulik

Monday, April 22, 2019

Amgen lightens the mood in a new TV ad for cholesterol med Repatha even as Amgen continues a patent dispute and price drops for the drug.

11. Amgen

by Arlene Weintraub

After two straight years at number 12 on FiercePharma’s list of the top pharma companies by revenues, Amgen moved up one spot with 2018 sales of $23.75 billion.